# U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™

> **NCT01706250** · PHASE4 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 20 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **OTHER:** MAXCLARITY II (2.5% BPO) Foam Cleanser
- **OTHER:** MAXCLARITY II (2.5% BPO) Foam Treatment
- **OTHER:** MAXCLARITY II (0.5% Salicylic Acid) Toner Foam
- **OTHER:** PROACTIV (2.5% BPO) Renewing Cleanser
- **OTHER:** PROACTIV (2.5% BPO) Repairing Lotion
- **OTHER:** PROACTIV (2.5% BPO) Revitalizing Toner

## Key facts

- **NCT ID:** NCT01706250
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09-01
- **Primary completion:** 2010-01-01
- **Final completion:** 2010-01-25
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01706250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01706250, "U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT01706250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*